ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
John R. Benfield
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, J. R.
Right arrow Articles by Tesluk, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, J. R.
Right arrow Articles by Tesluk, H.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 1995;60:32-36
© 1995 The Society of Thoracic Surgeons

Successful Xenotransplantation of Human Lung Cancer Correlates With the Metastatic Phenotype

Jeremy R. Johnson, BA, William G. Hammond, MD, John R. Benfield, MD, Henry Tesluk, MD

Division of Cardiothoracic Surgery, University of California, Davis, School of Medicine, Sacramento, California

Background. Occult micrometastases could explain deaths from stage I non–small cell lung cancer (NSCLC) after complete resections. If patients who have occult metastases could be identified, systemic therapy might be beneficial.

Methods. Non–small cell lung cancers from 81 patients in stages I, II, and III were transplanted to nude beige mice. Mean follow-up was 22.5 months (2 to 61 months).

Results. Twenty-one xenotransplants successfully took, and seven metastasized in the nude mice. Neither the predominant cell type nor the incidence of lymph node metastases correlated with the results of xenotransplantation. Of the 21 patients whose NSCLCs took in xenotransplantation, 13 (61.9%) have had development of metastases, and 9 (42.9%) have died of the cancer. Among the 57 patients whose NSCLCs did not take, 14 (24.6%) have had development of metastases, and 9 (15.8%) have died of their cancer. The higher incidence of metastases in association with xenotransplant take is significant (p = 0.0032).

Conclusions. Patients whose NSCLCs take in xenotransplantation are at high risk for metastases. The xenotransplantation model is a step toward facilitating precise cellular biologic definition of the metastatic propensity of human NSCLC.


Related Article

Discussion
Ann. Thorac. Surg. 1995 60: 36-37. [Extract] [Full Text]



This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
J. Merk, J. Rolff, M. Becker, G. Leschber, and I. Fichtner
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Eur. J. Cardiothorac. Surg., September 1, 2009; 36(3): 454 - 459.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. J. Landreneau, D. J. Sugarbaker, M. J. Mack, S. R. Hazelrigg, J. D. Luketich, L. Fetterman, M. J. Liptay, S. Bartley, T. M. Boley, R. J. Keenan, et al.
WEDGE RESECTION VERSUS LOBECTOMY for STAGE I (T1 N0 M0) NON-SMALL-CELL LUNG CANCER
J. Thorac. Cardiovasc. Surg., April 1, 1997; 113(4): 691 - 700.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1995 by The Society of Thoracic Surgeons.